Antiretroviral Therapy
Novel fungal polyketide inhibits HIV-1 integrase activity
Published in AIDS Weekly, August 16th, 2004
"HIV-1 integrase is a critical enzyme for replication of HIV, and its inhibition is one of the most promising new drug targets for anti-retroviral therapy with potentially significant advantages over existing therapies," investigators in the United States wrote."
The "isolation, structure elucidation, and absolute stereochemistry of integrasone, a novel polyketide, derived from an unidentified sterile mycelium" is described," said K.B. Herath and colleagues.
The authors reported, "This bicyclic dihydroxy epoxide lactone inhibited the strand transfer reaction of HIV-1...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of AIDS Weekly
Source: AIDS Weekly (2004-08-16)
More Articles from AIDS Weekly
- Antiretroviral Drug Resistance
Long-term suppression of HIV RNA with HAART occur despite virus evolution - Antiretroviral Therapy
Addition of tenofovir decreases AUC for atazanavir in HIV-treated patients - HIV/AIDS Research
New generation of SNV-based vectors may be used to block HIV-1 replication - HIV/AIDS Screening
Use of two HIV antibody screening tests increase false-positive rate - Perinatal HIV/AIDS
Rapid HIV testing during labor links HIV-positive pregnant women to treatment - AIDS/HIV Diagnosis
Performance of rapid HIV antibody detection assays evaluated - More from this issue of AIDS Weekly
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
